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Abstract 10 
This short review describes our work on the development of dendrimeric antagonists of DC-11 
SIGN, a Dendritic Cells (DCs) receptor recognizing highly mannosylated structures and 12 
primarily involved in the recognition of viruses, such as HIV. The structure of pseudo-di-13 
mannoside and pseudo-tri-mannoside compounds was first finely modified to obtain DC-14 
SIGN ligands more stable and selective than mannose. Their DC-SIGN affinity differences 15 
were amplified once presented on multivalent dendrimer-like scaffolds, including poly-alkyne 16 
terminated and phenylene-ethynylene rod-like ones. Libraries of mannosylated dendrimers 17 
were synthesized, improving their stability and maximizing their monodispersity.  The effect 18 
of the dendrimers valency, structure and size on DC-SIGN affinity and antiviral potency was 19 
investigated. Both the valency and the topology of the architectures were revealed as key 20 
parameters for activity optimization, together with the intrinsic affinity of the monovalent 21 
ligand. The stability, rigidity and length of the scaffolds were also tuned. The design of 22 
geometrically adapted scaffolds afforded one of the most potent inhibitors of DC-SIGN-23 
mediated HIV infections to date. This monodispersed, not cytotoxic and highly active 24 
compound was also tested with DCs; its internalization into endolysosomal compartments and 25 
its ability to induce the overexpression of signaling molecules makes it a good precursor to 26 
produce pathogen-entry inhibitors with immunomodulant properties.  27 
 28 
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Introduction 31 
Human immunodeficiency virus (HIV) is still a huge health problem of the 21st century, 32 
causing the death of over 1 million people per year from AIDS-related illnesses1. Waiting for 33 
an effective HIV vaccine2, the search for HIV entry-inhibitors represents a promising strategy 34 
to prevent HIV infection. HIV mainly targets Dendritic Cells (DCs), monocyte/macrophage 35 
lineage cells, and CD4+ T-lymphocytes3. Both receptor-mediated and non-specific 36 
electrostatic interactions drive the contact between the virus and the host cells. The discovery 37 
of artificial molecules able to efficiently antagonize one or a combination of these interactions 38 
goes in the direction of producing powerful microbicides. Nano-sized compounds have shown 39 
promising potential as effective inhibitors of viral infections4. Several classes of dendrimers 40 
have been designed and used to block different HIV-host cells interactions, targeting either 41 
cellular receptors or the viral envelope; their application as HIV entry-inhibiting microbicides 42 
has been recently reviewed5.  43 
In this short review, we will describe the research that has been carried out in our group for 44 
the past decade, focusing on the discovery of microbicides that operate by antagonizing the 45 
dendritic cell receptor DC-SIGN. DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-46 
integrin) is a trans-membrane lectin expressed at the surface of immature dendritic cells, 47 
particularly of dermal and mucosal tissue, and involved in the early stages of HIV infection6. 48 
DC-SIGN recognizes also other pathogens, including Ebola or Dengue viruses, promoting 49 
viral transmission and dissemination7. This lectin is a tetramer presenting four carbohydrate 50 
recognition domains (CRDs) that bind to highly mannosylated and fucosylated structures in a 51 
calcium-dependent manner. As for many other lectins, the affinity of DC-SIGN for its glycan 52 
ligands is only weak8 and strong binding is obtained, both in Nature and by synthetic 53 
antagonists, using multivalency. DC-SIGN antagonists have been produced functionalizing 54 
various multivalent platforms, including dendrimers, with mannose and oligomannoses9,10. In 55 
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parallel, our strategy consisted first of the design and the synthesis of unnatural monovalent 56 
glycoconjugate mimetics, more complex and possibly more active and selective than mannose 57 
itself. Secondly, the most promising candidates were used for the synthesis of polyvalent 58 
constructs, mostly based on dendrimers or dendron scaffolds. The effect of the dendrimers 59 
valency, structure and size on DC-SIGN affinity and antiviral potency has been investigated. 60 
For this endeavour we have used both real dendrimers/dendrons and dendrimer-inspired 61 
structures, i.e. molecules that lack a proper nucleus and repeated layers, but still are 62 
symmetrical and branched.   63 
 64 
Monovalent ligand optimization 65 
The high mannose glycan (Man)9(GlcNAc)2 (Figure 1) is one of the main carbohydrate 66 
ligands recognized by DC-SIGN; it is found in multiple copies on the HIV envelope 67 
glycoprotein gp120. Its terminal branches Manα1-2Man and Manα1-2 Manα1-6 Manα are 68 
both involved in binding with the protein11, although recent studies indicate that the main 69 
interaction may occur through the oligosaccharide branched trimannose core12.  70 
We have shown that pseudo-di-mannoside 113,14 and pseudo-tri-mannoside 215,16 (Figure 2), 71 
where one of the mannose residues has been replaced by an appropriate conformationally 72 
constrained cyclohexane ring, perform as structural and functional mimics of the natural 73 
sugars, while being stabilized against enzymatic hydrolysis13.   74 
Both ligands 1 and 2 bind to DC-SIGN in the carbohydrate recognition domain, as shown by 75 
the X-ray structure of their protein complexes17,18. The DC-SIGN affinity of these monovalent 76 
ligands was estimated by Surface Plasmon Resonance (SPR) competition experiments, 77 
whereby their ability to inhibit DC-SIGN binding to a highly mannosylated surface was 78 
measured. In these experiments, where both the lectin and the antagonists are free in solution, 79 
the pseudo-trisaccharide 2 (IC50 125 μM) was found to be ca. one order of magnitude more 80 
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potent than the corresponding pseudo-disaccharide 116, which in turn has the same activity of 81 
the natural sugar Manα1-2Man (IC50 ca. 1 mM)17, but is significantly less cytotoxic in cellular 82 
experiments14. Mimic 3 (Figure 2c), which is further functionalized on the aglycon, belongs to 83 
a group of modified ligands of intermediate DC-SIGN affinity (IC50 300 μM) that showed 84 
selectivity for DC-SIGN against similar C-type lectin receptors involved in protection 85 
mechanisms against HIV19.  86 
 87 
Dendrimer optimization 88 
Protein-carbohydrate interactions are relatively weak, with dissociation constants often lying 89 
in the low millimolar range. Nonetheless, high affinity can be achieved through multiple 90 
interactions. Therefore, in Nature lectin receptors present either multiple carbohydrate 91 
recognition domains or an oligomeric structure allowing multiple binding towards the target 92 
glycans, usually exposed in several copies as glycoconjugates forming polyglycosylated 93 
surfaces. Multivalent interactions affect lectin affinity and also modulate lectin selectivity. 94 
For these reasons, to compete with this kind of interactions and efficiently bind to natural 95 
proteins, artificial glycoconjugates should be multivalent20. The multivalent binding modes 96 
that can be exploited include chelation, i.e. the simultaneous binding of more than one protein 97 
binding site by a single multivalent system (Figure 3a), as well as other non-chelating effects, 98 
such as the statistical rebinding effect (Figure 3b), caused by enhancement of the local 99 
concentration of the active ligands, and the ability of the multivalent structures to 100 
cluster/aggregate receptors (Figure 3c)21.  101 
Notably, the density of sugar residues, the topology of presentation and the orientation have 102 
emerged as important parameters able to shape protein/carbohydrate interactions affinity and 103 
selectivity22,23. In the design of polyglycosylated DC-SIGN antagonists we made use of 104 
dendrimeric core structures as valuable scaffolds for the multivalent presentation of ligands. 105 
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These architectures enabled efficient generation of monodisperse constructs with control over 106 
valency and spatial arrangement. In particular, dendrimers were decorated with the optimized 107 
monovalent glycomimetic ligands 1-3, which have shown a significant affinity for DC-SIGN. 108 
In a first attempt, we investigated how valency and the nature of the monovalent ligands 109 
affect the affinity towards the receptor. We then tuned the stability, rigidity and length of the 110 
scaffolds, in order to produce ligands able to match the distance between two contiguous DC-111 
SIGN binding sites, therefore being able to undergo a plurality of multivalent mechanisms 112 
and enhance their bioactivity, while maintaining a moderate valency.  113 
 114 
Polyester (Boltorn-type) scaffolds  115 
The first class of multivalent glycocompounds was prepared in collaboration with the group 116 
of Javier Rojo (CSIC-Seville) using 2,2-bis(hydroxymethyl)propionic acid (bis MPA) derived 117 
polyester dendrons and dendrimers (Boltorn-type). Rather than using polydisperse 118 
commercial scaffolds, the polyesters were prepared in a monodisperse manner. Both the 119 
tetravalent dendron 4 and the 32-valent dendrimer 5 (Figure 4) were synthesized using bis 120 
MPA as building block, and introducing carboxylic acid residues at the dendrimer periphery 121 
by reaction with conveniently protected succinic acid moieties. Compounds 1 and 2, both 122 
tethered to an amino-terminated linker, were coupled to the dendrimers using HATU as the 123 
activating agent, in the presence of N,N-diisopropylethylamine. Final compounds 4.1, 4.2, 5.1 124 
and 5.2 (Figure 4) were obtained in high yields; the tetravalent compounds were completely 125 
monodisperse, whilst both 5.1 and 5.2 were loaded with 30-32 copies of the ligands, on 126 
average24.  127 
These compounds were tested as DC-SIGN ligands in SPR competition assays. Results 128 
showed a dependency on multivalent presentation, since the full dendrimers 5.1 and 5.2 (IC50 129 
= 1-2 μM) were two orders of magnitude more active than the corresponding tetravalent 130 
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dendrons 4 (IC50 = 120-220 μM). Surprisingly, though, the nature of the monovalent ligand 131 
did not affect the affinity significantly, since constructs of similar valency showed similar 132 
IC50s, despite the one order of magnitude difference observed at the monovalent level 133 
between 1 and 2. The same phenomenon was observed in an Ebola infection model24 and by 134 
testing 4.1, 4.2, 5.1 and 5.2 in a cellular model of HIV infection18. These data prompted us to 135 
reexamine in more detail the interaction of 2 with DC-SIGN by a number of biophysical 136 
techniques, which  allowed to conclude that the affinity measured for this molecule in our 137 
initial experiments was largely determined by a clustering mechanism in solution (Figure 3c). 138 
In other words, the two mannose units at both ends of 2 are able to interact simultaneously 139 
with two DC-SIGN tetramers by simultaneously binding to one CRD per tetramer18. This 140 
behavior leads to a high potency measured in all the experimental set ups where both the 141 
protein tetramer and 2 are in the same solution (e.g. in SPR competition experiments and in 142 
Isothermal Titration Calorimetry (ITC)). However, the clustering mechanism is lost when 2 is 143 
conjugated to a polyvalent scaffold, which prevents the reducing end mannose from reaching 144 
its target, and is also unlikely to be relevant in physiological conditions, where DC-SIGN is 145 
bound to the cellular membrane. As a result, further studies on pseudo-glycodendrimers 146 
targeted against DC-SIGN were mostly focused on the modified pseudo-dimannoside 3. 147 
From a practical point of view, the tetravalent dendrons 4.1 and 4.2 represent a good 148 
compromise between affinity and synthetic effort. However, both the polyester dendron 4.1 149 
and 4.2 suffer from chemical instability, since the unhindered succinyl ester moieties used to 150 
introduce carboxylic groups on the outer layer, are labile to nucleophiles, both under basic 151 
and mild acidic catalysis. For instance, 30 % of 4.2 was hydrolyzed after 6 h in water solution 152 
at physiological pH (7.4, PBS buffer, NMR investigation), highlighting its limit for in vivo 153 
applications. MS analysis of the product confirmed that the hydrolysis occurred at the 154 
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succinyl ester bond. Moreover, this instability prevents purification by reverse phase 155 
chromatography and hinders the scale up of the synthetic process.  156 
In order to achieve stabilized versions of the hydrolytically unstable constructs 4 (Figure 4), 157 
the synthesis of the analogous tetravalent dendron 4N was undertaken (Scheme 1)25. In 4N the 158 
labile succinyl ester bonds are replaced with more robust amide functionalities, that can be 159 
installed starting from the tetramine 6 (Scheme 1). A diglycolate linker 7, slightly longer and 160 
more hydrophilic than succinate, was selected in this design, thus preserving the water 161 
solubility of the molecule. Additionally, the length of the linker helped to minimize side 162 
reactions due to attack of the scaffold nitrogen atom over the activated carboxylic acids 163 
during the final functionalization of the dendron.  164 
Condensation of the tetracid 4N with the amino-tethered 1a and 2a led to dendrons 4N.1 and 165 
4N.2 (Figure 5), which were found to be fully stable both to chromatographic conditions and 166 
in water solution at physiological pH. These dendrons have also been tested as ligands for 167 
mouse Mannose Binding Lectin (MBL-C), a C-type lectin involved in the pathophysiology of 168 
brain ischemia/reperfusion injury26, and have shown activities similar to the lead 4.2.  169 
Additionally, functionalization of the dendron focal point with an azido-terminated tether was 170 
adopted to allow the convergent synthesis of higher valency constructs. In particular, 171 
exploiting Cu(I) catalyzed azide-alkyne cycloaddition (CuAAC), 4N.1 was further connected 172 
to a pentaerythritol derived scaffold 8 (Scheme 2). The resulting 16-valent compound 4.4N.1 173 
was almost 2-orders of magnitude more active than its precursor in an MBL-C binding 174 
assay25. 175 
 176 
Polyalkyne terminated scaffolds  177 
In a different approach, to further improve the synthetic accessibility and chemical stability of 178 
the dendrimers, new polyalkyne terminated scaffolds, with a valency ranging from 2 to 6, 179 
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were synthesized27. They were then decorated with azide-bearing ligands 1-3, or with 180 
mannose as a control, through CuAAC. Nondegradable glycodendrons and glycodendrimers 181 
with a valency of 3, 4 or 6 (9-11, Figure 6) were obtained, characterized by stable ether bonds 182 
and triazole connectors. In a convergent approach, the trivalent dendrons 9, bearing an azido 183 
group at the focal point, were used to build higher valency constructs (6-, 9-, 12- and 18-184 
valent 12.9, 13.9, 10.9 and 11.9) by combination with either the divalent, tetravalent or 185 
hexavalent scaffolds 12, 13, 10 and 11 (Figure 6). CuAAC allowed a full control over the 186 
targeted structure: all products were characterized by NMR spectroscopy and MALDI-MS 187 
analysis, and were stable for months in water solution.  188 
Compounds affinity for DC-SIGN was evaluated through SPR inhibition assays and the 189 
relative inhibitory potency (R.I.P.) values were compared (Figure 7, Relative inhibitory 190 
potencies (R.I.P.) are valency-corrected and calculated according as: 𝐼𝐶50,𝑚𝑜𝑛𝑜𝑣𝑎𝑙𝑒𝑛𝑡
𝐼𝐶50,𝑚𝑢𝑙𝑡𝑖𝑣𝑎𝑙𝑒𝑛𝑡×𝑣𝑎𝑙𝑒𝑛𝑐𝑦). 191 
Comparing constructs of the same valency, glycodendrimers bearing the monovalent ligand 3 192 
had lower IC50 values than the ones carrying 1, and all of them were more active than the 193 
simply mannosylated analogs (Figure 7) . Once again, dendrimers based on 2 behaved 194 
similarly to the corresponding derivatives of 1; moreover, the tetravalent and the hexavalent 195 
compounds 10.2 and 11.2 showed a R.I.P. < 1. This confirmed that the high activity of the 196 
monovalent ligand 2 is due to an outperforming binding mode not allowed for its multivalent 197 
derivatives. On the contrary, the activity of the multivalent presentations of compounds 1 and 198 
3 gradually increased by incrementing the valency. Remarkably, R.I.P. values obtained for 199 
dendrimers based on 3 grew faster with valency than those shown by the corresponding 200 
dendrimers based on 1 or on mannose (Figure 7). These results highlight that affinity 201 
differences at the monovalent level are amplified by multivalent presentation and support the 202 
importance of optimizing the structure of monovalent ligands. Tetravalent 10.1 and 10.2 had 203 
an analogous affinity for DC-SIGN with respect to 4.1 and 4.2, suggesting that, being the 204 
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valency equal, the shape of this type of dendrimers does not influence their activity to a 205 
significant extent. .   206 
Compounds 10.1, 10.3 and 11.3 were tested also in cellular infection models, by evaluating 207 
their ability to inhibit the DC-SIGN-mediated HIV infection of CD4+ T-cells. Also in this 208 
case, the activity of the monovalent ligand had a positive role, since 10.3 was more active 209 
than 10.1. The importance of the valency was also confirmed: the hexavalent compound 11.3 210 
was around 10 times more active than the tetravalent 10.3. Remarkably, despite the good 211 
results shown by glycodendrimers bearing mimic 3, a further valency increase, as in 13.9.3 212 
(Figure 6), was not practical, due to low water solubility of the constructs.  213 
Molecular dynamic simulations were used to estimate the maximum distance spanned by 214 
dendrimers 10.1 and 11.1 (as simpler models of 10.3 and 11.3, respectively), which in turn 215 
allowed to dissect the possible mechanisms of interaction between the glycodendrimers and 216 
DC-SIGN. Since the calculated maximum extension of 11.1 was 35.4 Å and the distance 217 
between two contiguous DC-SIGN binding sites in one tetramer is at least 38 Å28, the 218 
chelation mechanism was excluded. Remarkably, the hexavalent compound 11.1 had an IC50 219 
value comparable to that of 12.9.1, which is also hexavalent, but is built on a longer PEG 220 
core, suggesting that a flexible linker is not suitable to make the active ligands assuming the 221 
proper conformation for chelation.     222 
 223 
Phenylene-ethynylene rod-like scaffolds  224 
With the goal of further improving dendrimers activity by exploiting the chelation 225 
mechanism, the length and the rigidity of the scaffolds were optimized. In a collaboration 226 
with the group of Roland J. Pieters (Utrecht University), three phenylene-ethynylene rod-like 227 
spacers of different lengths (i.e. 8, 12.5 and 22 Å) were synthesized through multiple 228 
Sonogashira reactions and deprotection steps29. Their terminal triple bonds were exploited to 229 
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connect the glycomimetic moieties by CuAAC reactions. To this aim, trivalent dendrons 9.1 230 
and 9.3 were employed, as well as the monovalent ligands 1 and 3 and their elongated 231 
versions, characterized by a PEG linker having the same length of the dendron chain30. The 232 
structures of the obtained hexavalent dendrimers (14.9.1, 15.9.1, 16.9.1, 14.9.3, 15.9.3, 233 
16.9.3) and divalent controls (16.1, 16.3 and 14.1L, 15.1L, 16.1L, 14.3L, 15.3L, 16.3L) are 234 
depicted in Figure 8.   235 
Molecular dynamics simulations showed that all these constructs have the potential to chelate 236 
two contiguous DC-SIGN binding sites: at maximum extension both the shortest dendrimer 237 
14.9.1 and the longest one 16.9.1 are longer than 4 nm. As before, SPR competition assays 238 
were performed to measure their IC50 and R.I.P. values (Figure 9). The hexavalent derivatives 239 
of 3 (14.9.3, 15.9.3 and 16.9.3) could not be evaluated appropriately in this format, because 240 
their affinity reached the lower limit of the assay (Figure 9). Nonetheless, valuable 241 
information could be gathered concerning the effect of the spacers on the dendrimers’ 242 
activity. 243 
As expected, compounds based on the more active ligand 3 outperformed those based on 1 244 
(see, for instance, divalent 16.1 and 16.3). The bioactivity was also clearly dependent on the 245 
valency, since hexavalent compounds were more active than the corresponding divalent ones 246 
(compare 16.9.1 and 16.1), demonstrating the positive effect of increasing the local ligand 247 
concentration. Entropic penalties were paid by the structures characterized by the flexible 248 
PEG linker (1.L and 3.L derivatives); indeed, 16.1 and 16.3 were about two times more active 249 
than 16.1.L and 16.3.L, respectively. Finally, IC50s decreased regularly with the length of the 250 
rod, suggesting that the chelation mechanism may become increasingly accessible.  251 
For the hexavalent derivatives of 3 a more sensitive cellular HIV infection study was 252 
performed, revealing again a clear dependency on the length of the rod core. In particular, the 253 
bioactivity increased by about one order of magnitude from 11.3 to 14.9.3, by simply 254 
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inserting the shortest rod as the dendrimer core, and it was highest for the longest 16.9.3. The 255 
valency effect was also confirmed, since hexavalent compounds were more active than the 256 
divalent ones. IC50 values were measured for 14.9.3, 16.9.3, 16.3 as 67 nM, 24 nM and 161 257 
nM, respectively. To the best of our knowledge, 16.9.3 is one of the most potent inhibitors of 258 
the DC-SIGN-mediated trans HIV infection described up to date, despite its relatively 259 
moderate valency and strengthened by its controlled and well characterized structure. This 260 
result clearly highlights how the combination of optimized monovalent ligands with fine-261 
tuned multivalent constructs of controllable size can maximize the effect of valency when 262 
targeting a multivalent receptor. 263 
 Remarkably, even if these dendrimer-like compounds, bearing a lipophilic core and 264 
hydrophilic carbohydrate groups, are endowed with amphiphilic properties, they do not 265 
significantly aggregate in aqueous solution, as shown using Dynamic Light Scattering, 266 
Analytical Ultracentrifugation and a number of other biophysical techniques31. Hence, their 267 
performances in infection studies can be correctly interpreted based on their individual 268 
structure.   269 
 270 
Biological characterization 271 
Three of the dendrimers described above, 4.232, 11.333 and 16.9.334, underwent further 272 
biological assays to achieve a fuller characterization of their effect. Importantly, none of the 273 
compounds was found to be toxic against the tested cell lines, and both 4.2 and 11.3 did not 274 
alter the viability of human cervical explants up to a concentration of 1 mM.  275 
In particular, dendron 4.2 and dendrimer 11.3 were tested as inhibitors of HIV infection on 276 
explants obtained from human uterine cervix, to achieve a better approximation of in vivo 277 
conditions. To this aim, tissue explants were exposed to different types of R5 tropic HIV-1, 278 
including the laboratory adapted BaL and clinical primary isolates, in the presence of 279 
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glycoderivatives. Infection was reduced by more than 85 % with 1 mM 4.2 and 0.5 mM 11.3, 280 
demonstrating that these inhibitors are good precursors to be further optimized and formulated 281 
as microbicide drugs.  282 
It is well-known that the DC-SIGN binding to a ligand can activate and regulate the immune 283 
response35, therefore DC-SIGN binders are also studied for the development of vaccines and 284 
immunomodulants. The activation of DC-SIGN signaling by the dendrimers synthesized in 285 
our group was investigated to assess if they stimulate the production of factors able to 286 
interfere with HIV infection and if they are suitable as immunomodulants and vaccine 287 
adjuvants. In this study, the expression of cytokines, chemokines and genes involved in 288 
immune responses was evaluated after immature Monocyte Derived Dendritic Cells 289 
(iMDDCs) interaction with DC-SIGN antagonists. Preliminarily, the behavior of 4.2 was 290 
explored32, showing that it induced an increase of the production of β chemokines known to 291 
suppress HIV-1 R5 tropic strain replication36. A similar activity was observed for 11.333 and 292 
16.9.334, that also stimulated an impressive production of antiviral and pro-inflammatory 293 
cytokines, as well as of co-stimulatory molecules having a role in the activation of naïve T 294 
cells. Additional cytokines and proteins that promote Dendritic Cells differentiation, 295 
development, survival and activation were overexpressed by treating iMDDCs with 16.9.3.  296 
Although a direct comparison between the effects of the tested compounds could not be 297 
drawn, since experiments were conducted on different healthy donors, using different 298 
techniques and experimental settings, it was noticed that the inflammatory response 299 
stimulated by 16.9.3 was less pronounced than that caused by 8.3. This is an important 300 
element to acquire, since an excessive immune response can result in tissue damage (and even 301 
death). It was therefore concluded that these compounds and, in particular, the most active 302 
DC-SIGN antagonist 16.9.3, have a potential use as adjuvants and immunostimulants in the 303 
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formulation of vaccines for HIV and, generally, mucosal pathogens. Further studies in both ex 304 
vivo and in vivo models will be required.  305 
Exploiting the intrinsic fluorescence of its rod core, the cellular uptake and internalization 306 
route of 16.9.3 within human iMDDCs was investigated by means of fluorescence 307 
microscopy at varying time and temperature intervals34. It was observed that 16.9.3 is 308 
internalized by DCs already after 10 min of incubation at room temperature, but not at 4 °C, 309 
an indication that uptake occurs through an energy-dependent mechanism, such as the 310 
receptor-mediated one.  311 
Finally, confocal images with fluorescent tracers used to mark specific sub-cellular organelles 312 
revealed that 16.9.3 is internalized mainly to lysosomes and that it also transits through and 313 
resides in early endosomes for a quite prolonged period of time. These pulse-chase 314 
experiments showed that the dendrimer uptake is rapid and confirmed that the molecule has 315 
the potential to elicit an immune response that may be exploited for the development of 316 
vaccines.  317 
 318 
Summary and outlook 319 
We have here presented the results of our search for efficient antagonists of DC-SIGN, a C-320 
type lectin recognizing highly mannosylated structures, and involved in the recognition 321 
process of pathogens such as HIV, Ebola and Dengue viruses. Rather than directly using 322 
mannose- or oligomannose derivatives, our strategy has first been devoted to the optimization 323 
of glycomimetic monovalent DC-SIGN ligands. We have then combined the most promising 324 
monovalent ligands with several types of dendrimer-like scaffolds, to produce multivalent 325 
materials targeted against C-type lectins and in particular DC-SIGN. The activity trend of the 326 
monovalent ligands was reflected in the bioactivity of the dendrimers, thus highlighting the 327 
importance of ligand optimization. Also the valency influenced dendrimers activity; indeed, 328 
15 
 
among each dendrimer sub-class, the activity generally increased by increasing the valency. 329 
The size of the dendrimers was finally tuned using rigid rod-like cores of controlled length, in 330 
order to control the relative orientation and the distance spanned by the active ligands. In this 331 
way, we synthesized a class of dendrimer-like molecules that can reach simultaneously two 332 
adjacent DC-SIGN binding sites within the tetramer carrying to each site a small cluster of 333 
glycomimetic ligands. These systems, thus, can exploit more than one multivalency 334 
mechanism (e.g. chelation, statistical rebinding), which results in a major potency 335 
enhancement compared to shorter or more flexible constructs. With an appropriate 336 
combination of monovalent ligands, rod-core and valency, the hexavalent compound 16.9.3, 337 
one of the most potent inhibitors of the DC-SIGN-mediated HIV infection up to date, was 338 
obtained. This result showed how the rational design of artificial ligands helps in obtaining 339 
powerful compounds while retaining a moderate valency, which allows to deal with perfectly 340 
monodisperse and well-characterized species. DC-SIGN antagonists such as 16.9.3 are 341 
effective precursors for further derivatizations and appropriate formulations, with the aim of 342 
producing topical microbicides as pathogen-entry inhibitors. Moreover, we have observed that 343 
16.9.3 is internalized by dendritic cells and routed to endolysosomal compartments. These 344 
features, together with its ability to induce the overexpression of signaling molecules involved 345 
in immune responses, make 16.9.3 interesting as an immonomodulator and vaccine adjuvant.  346 
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Figure captions 425 
Figure 1: Chemical structure of (Man)9(GlcNAc)2 glycan; the disaccharide Manα1-2Man and 426 
the trisaccharide Manα1-2 Manα1-6 Manα are encircled. 427 
Figure 2: Structure of the synthesized pseudo-mannosylated compounds: a) pseudo-428 
disaccharide 1 mimics the Manα1-2Man disaccharide; b) pseudo-trisaccharide 2 mimics the 429 
Manα1-2Manα1-6Man trisaccharide; c) bis-amide-substituted pseudo-disaccharide 3. 430 
Figure 3: Possible affinity-enhacement mechanisms occurring between a multivalent ligand 431 
(black) and a multivalent protein (gray): a) chelation; b) statistical rebinding; c) protein 432 
aggregation. 433 
Figure 4: Structure of scaffolds 4 and 5 and the corresponding tetravalent 4.1 and 4.2 434 
glycosylated dendrons and 32-valent glycosylated 5.1 and 5.2 dendrimers.  435 
Figure 5: Structure of tetravalent dendrons 4N.1 and 4N.2, stabilized by replacing the succinyl 436 
ester bond with an amido bond.  437 
Figure 6: Structure of the glycodendrimers based on monovalent mannose, 1, 2 or 3 and 438 
multivalent polyalkyne terminated scaffolds.  439 
Figure 7: IC50 (empty white bars) and relative inhibitory potency (R.I.P.) (black bars) values 440 
of 1, 2, 3 and mannose multivalent derivatives, tested as DC-SIGN binders through SPR 441 
competition assays.  442 
Figure 8: Structure of the glycodendrimers based on monovalent ligands 1 or 3 and rigid 443 
phenylene-ethynylene scaffolds. 444 
Figure 9: IC50 (empty white bars) and relative inhibitory potency (R.I.P.) (black bars) values 445 
of rod-based derivatives of 1 and 3, tested as DC-SIGN binders by SPR competition assays. 446 
Scheme 1: Synthesis of tetramine 6 and  of the tetravalent dendron  4N  447 
Scheme 2: Synthesis of the 16-valent compound 4.4N.1 from dendron 4N.1. 448 
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